Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Neoadjuvant chemotherapy may improve overall survival (OS) in ‘borderline’ resectable pancreatic cancer (RPC). Whether the results are the same in upfront RPC is unknown. MATERIALS AND METHODS: To evaluate the association of neoadjuvant treatment and survival outcomes in RPC, a systemati...

Descripción completa

Detalles Bibliográficos
Autores principales: Uson Junior, P.L.S., Dias e Silva, D., de Castro, N.M., da Silva Victor, E., Rother, E.T., Araújo, S.E.A., Borad, M.J., Moura, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024142/
https://www.ncbi.nlm.nih.gov/pubmed/36638709
http://dx.doi.org/10.1016/j.esmoop.2022.100771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024142/
https://www.ncbi.nlm.nih.gov/pubmed/36638709
http://dx.doi.org/10.1016/j.esmoop.2022.100771

Ejemplares similares